As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development. However, their complex structures necessitate sophisticated bioanalytical strategies to effectively assess pharmacokinetics (PK) and immunogenicity.​

KCAS Bio is excited to invite you to an insightful webinar through Xtalks titled “Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics,” scheduled for Thursday, April 17, 2025, at 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central). This session will dive into the latest advancements in conjugation technologies and discuss optimal bioanalytical approaches to support these innovative therapies.​

Key Topics to Be Explored:

  • Comprehensive PK Assessment Methods: An overview of the necessary pharmacokinetic methods tailored for conjugated drugs, including a discussion on various platforms utilized for PK assessments and strategies for selecting the appropriate platform.​
  • Immunogenicity Evaluation Strategies: Insights into effective immunogenicity assessment techniques, highlighting critical reagents recommended for supporting conjugated drugs and addressing challenges associated with multiplexing PK assays.​
  • Regulatory Considerations: An examination of regulatory expectations for the bioanalysis of conjugated drugs, offering guidance on ensuring compliance throughout the drug development process.​
  • Real-World Case Studies: Presentation of practical examples illustrating PK analyses and immunogenicity evaluations of conjugated drugs, providing attendees with tangible insights into the application of discussed strategies.​

Meet the Expert Speakers:

  • Dr. Dominic Warrino, Senior Director of Scientific Services at KCAS Bio: With extensive experience in developing and validating bioanalytical methods across various therapeutic modalities, Dr. Warrino leads a team specializing in PK, immunogenicity, pharmacodynamics (PD), and biomarker assessments.​
  • Dr. Dawn Dufield, Scientific Officer for Mass Spectrometry at KCAS Bio: Boasting over two decades of expertise in quantitative large and small molecule LC-MS/MS, Dr. Dufield has been instrumental in pioneering hybrid LC-MS techniques and has made significant contributions to ADC bioanalysis.​

Who Should Attend:

This webinar is particularly relevant for professionals involved in drug conjugate development, including those responsible for PK and anti-drug antibody (ADA) testing, as well as the implementation of related bioanalytical strategies. Attendees will gain valuable knowledge on the latest bioanalytical techniques for ADCs, ARCs, and antibody-peptide conjugates, and will be better equipped to navigate the complexities associated with developing and analyzing these advanced biotherapeutics.​

Register Now:

Don’t miss this opportunity to enhance your understanding of cutting-edge PK and immunogenicity strategies for next-generation conjugated biotherapeutics. Register now to secure your spot and gain valuable insights from industry experts.